Promotional product theaters provide time for presentation of new research findings on products, showcasing of product details, demonstrations and highlights of new products. These sessions are promotional and are not eligible for continuing education credits. Attendance at the product theaters is first-come, first-served and seating is limited. A refreshment break or meal is provided at each event except for Monday afternoon. Registration will be required for Physician Payment Sunshine Act reporting.
All product theaters will be held in 301 C in the Phoenix Convention Center
Laughing and crying are natural human expressions, but what if these responses became misaligned with our feelings, firing excessively or without warning? What if you couldn’t control it? This is a reality for nearly 2 million Americans suffering from PseudoBulbar Affect (PBA), a neurologic condition marked by uncontrollable outbursts of crying and/or laughing in people with certain brain diseases or injuries.
BEYOND LAUGHTER & TEARS is an inspiring documentary featuring six patients living with PBA. One of them is Dyanna Hurley, a former competitive ballroom dancer and nurse, who suffered a stroke that led to loss of mobility and sudden bouts of unprovoked and uncontrollable crying that was initially diagnosed as depression, though she didn’t feel depressed. We invite you to view a portion of the film, and gain first-hand knowledge of this under-recognized, often misunderstood and potentially stigmatizing condition as Roger Sommi leads an educational discussion with Dyanna and her sister Kathie and PBA expert, Dr. Jason Caplan.
Roger Sommi, PharmD, FCCP, BCPP
Associate Dean, UMKC School of Pharmacy at MU
Professor, Pharmacy Practice and Psychiatry
School of Pharmacy
University of Missouri-Kansas City
Kansas City, Missouri
Jason Caplan, MD, FAPM
Chair of Psychiatry, Creighton University School of Medicine
St. Joseph's Hospital and Medical Center
Professor of Psychiatry
Creighton University School of Medicine
Review the efficacy, safety, pharmacology and innovative delivery systems of Janssen long-acting therapies in patients with schizophrenia.
Jose Andres Rey, MS, PharmD, BCPP
Associate Professor of Pharmacy Practice
Nova Southeastern University College of Pharmacy
Fort Lauderdale, FL
Pre-register online (preferred)
Given that nearly 60% of patients treated for depression in the United States receive treatment in a primary care setting, it is of the utmost importance for clinicians to understand how to adequately recognize and treat the symptoms of depression. This program will discuss the under diagnosis of Major Depressive Disorder, the barriers to patients receiving appropriate treatment in the primary care setting, and the potential consequences of inadequate treatment. Strategies to improve recognition and overcome barriers to treatment will be reviewed.
Glen Stimmel, PharmD
University of Southern California
Los Angeles, CA